Association of CD34 Expression with Future Relapse in Pediatric T-cell Acute Lymphoblastic Leukemia

AuthorHui Gaoen
AuthorFengqing Caien
AuthorHongqiang Shenen
AuthorHua Songen
AuthorShilong Yangen
OrcidHui Gao [0000-0002-7811-9242]en
OrcidHongqiang Shen [0000-0001-7188-5289]en
Issued Date2024-12-31en
AbstractBackground: Developing novel prognostic markers is crucial for childhood T-cell acute lymphoblastic leukemia (T-ALL). Objectives: This study aimed to investigate whether the prognostic impact of CD34, a progenitor marker, is associated with outcomes. Methods: This retrospective cohort study included 82 risk-adapted pediatric patients with T-ALL who were treated under the National Protocol of Childhood ALL in China (NPCLC)-ALL2008 from March 2008 to December 2016. Results: CD34 expression was observed in 37.8% of all T-ALL patients, with a median expression level of 62.7%. Patients with CD34 expression had a favorable event-free survival (EFS, 74.2% [66.3% - 82.1%]) with a hazard ratio of 0.69 (P = 0.33) and a reduced cumulative incidence of relapse (CIR, 22.6% [15.0% - 30.2%]; P = 0.86) at five years. Even after adjusting for potential factors and competing events in multivariable regression models, there was no connection between the CD34 immunophenotype and the risk of recurrence. Conclusions: CD34 expression did not serve as a predictive factor for relapse in this limited series. Larger multicenter studies are recommended to determine whether this biomarker at initial diagnosis can predict outcomes.en
DOIhttps://doi.org/10.5812/ijp-141344en
KeywordT-cell Acute Lymphoblastic Leukemiaen
KeywordCD34en
KeywordChildrenen
KeywordRelapseen
PublisherBrieflandsen
TitleAssociation of CD34 Expression with Future Relapse in Pediatric T-cell Acute Lymphoblastic Leukemiaen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijp-34-6-141344-publish-pdf.pdf
Size:
285.34 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF